Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.50 |
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2528913 | 0.88 | TRPV1 (0.47) | TRPV1MBOAT4PDE10AMCHR1FFAR2 | |
| SCHEMBL2527534 | 0.80 | SLC6A4 (0.43) | TRPV1MBOAT4PDE10AMCHR1CHRNB2 | |
| SCHEMBL25510950 | 0.78 | MBOAT4 (0.41) | TRPV1MBOAT4 | |
| SCHEMBL25510877 | 0.76 | TRPV1 (0.48) | TRPV1MBOAT4 | |
| SCHEMBL13136015 | 0.75 | MBOAT4 (0.46) | TRPV1MBOAT4 | |
| SCHEMBL25510952 | 0.73 | TRPV1 (0.41) | TRPV1 | |
| SCHEMBL25510881 | 0.72 | MBOAT4 (0.53) | TRPV1MBOAT4 | |
| SCHEMBL2529166 | 0.70 | TRPV1 (0.49) | TRPV1MBOAT4 | |
| SCHEMBL2528952 | 0.69 | TRPV1 (0.44) | TRPV1MBOAT4 | |
| SCHEMBL2531667 | 0.68 | TRPV1 (0.48) | TRPV1MBOAT4FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147428-A1 | BENZIMIDAZOLONE-BASED CINNAMAMIDE DERIVATIVE AS TRPV1 ANTAGONIST AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF PAIN CONTAINING SAME AS ACTIVE INGREDIENT | JMACKEM CO., LTD (KR) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147428-A1 | BENZIMIDAZOLONE-BASED CINNAMAMIDE DERIVATIVE AS TRPV1 ANTAGONIST AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF PAIN CONTAINING SAME AS ACTIVE INGREDIENT | TRPV1, TRPA1, TRPV5 | TRPV1 1/4885MBOAT4 2753/4885PDE10A 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.